95P Additional survival follow-up of TACTICS-L: Transcatheter arterial chemoembolization therapy (TACE) in combination strategy with lenvatinib in (LEN) patients with unresectable hepatocellular carcinoma in Japan

Abstract

TACTICS-L is a prospective study to evaluate safety and efficacy of combination of TACE and LEN in HCC patients who are not eligible for curative therapy (uHCC). The primary analysis was conducted at cutoff date of April 2021 (minimum follow-up 12 months), and median progression-free survival (PFS), the primary endpoint, was 24.4 months. Regarding the secondary endpoint, the median overall survival (OS) was 25.9 months, and best objective response was 88.7% (CR 67.7%) 1). Here we report an additional follow-up on PFS and OS.